Rradiosensitizer· Health · 6 sources · Sep 14, 2026StoryNanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer TrialNanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.Health· Sep 14, 2026+302ShareSam Okafor·Sep 14, 2026Top commentThe fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.00ReplyGenius replyShareWrite a comment…
